What's new in atopic eczema? An analysis of systematic reviews published in 2008 and 2009.
This review summarizes clinically important findings from nine systematic reviews of the causes, treatment and prevention of atopic eczema (AE) published between August 2008 and August 2009. Two systematic reviews concluded that there is a strong and consistent association between filaggrin (FLG) mutations and development of eczema. The associations between FLG mutations and atopic sensitization, rhinitis and asthma are weaker than between FLG mutations and eczema, especially if those who also have eczema are excluded. The relationship between transforming growth factor levels in breast milk and eczema development is still unclear. A further systematic review found no strong evidence of a protective effect of exclusive breastfeeding for at least 3 months against eczema, even in those with a positive family history of atopy. Based on a systematic review and meta-analysis of six randomized controlled trials, supplementation with omega-3 and omega-6 oils is unlikely to play an important role in the primary prevention of eczema or allergic diseases in general. There is little evidence to support dietary restrictions of certain foods in unselected children with AE. There is also little evidence to suggest a clinically useful benefit from using probiotics in patients with established eczema. A systematic review of topical pimecrolimus and tacrolimus added little additional information to previous reviews, and did not provide any new data on long-term safety. Both of these drugs work in AE, and may reduce flares and usage of topical corticosteroids; however, there is still uncertainty about how they compare with topical corticosteroids.
Batchelor
J M
JM
Addenbrooke's Hospital, Cambridge, UK.
Grindlay
D J C
DJ
Williams
H C
HC
D001942:Breast Feeding; D003876:Dermatitis, Atopic / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D043371:Fatty Acids, Omega-6 / Q000627:therapeutic use; D000091344:Filaggrin Proteins; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007381:Intermediate Filament Proteins / Q000235:genetics; D008895:Milk, Human / Q000737:chemistry; D009154:Mutation; D019936:Probiotics / Q000627:therapeutic use; D016559:Tacrolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000032:analysis
C000717249:FLG protein, human; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D000091344:Filaggrin Proteins; D007166:Immunosuppressive Agents; D007381:Intermediate Filament Proteins; D016212:Transforming Growth Factor beta; C117268:pimecrolimus; D016559:Tacrolimus